Nomura

Alkem Laboratories has priced its Rp13.5bn ($202.1m) IPO at the top end of its range, following a burst of demand for the Indian healthcare sector in the past month.

Alkem Laboratories is set to price its Rp13.5bn ($202.1m) IPO at the top of the range after investors piled into the trade, buoyed by healthy demand for the Indian pharmaceutical sector.

Nomura's head of southeast Asia debt capital markets is understood to be leaving the firm at the end of this month.

YiChang HEC ChangJiang Pharmecutical Co has settled on a price range for its H-share float, with bookbuilding to kick off on December 14.

David Lloyd Leisure, the TDR Capital-owned UK gym and spa firm, and Cooper, the French pharmaceuticals distributor, widened loan pricing this week as the leveraged market became increasingly selective.

Two Indian healthcare companies closed extremely successful IPOs on Thursday, with Alkem Laboratories and Dr Lal Pathlabs fully covered mid-way through bookbuilding. And with India’s equity capital market buzzing with activity, bankers are telling their clients to seize the day before uncertainty sets in, writes John Loh.

Nomura’s Lorenz Altenburg is set to join CaixaBank in January, where he will head the firm’s fixed income syndicate in its recently established Corporate & Institutional Banking (CIB) division.

Cooper, the French pharmaceuticals distributor, has priced the term loan ‘B’ for its acquisition by Charterhouse at 475bp over Euribor, with an original issue discount of 99.5, the wide end of initial talk that began at 450bp.

Santander UK has beaten a path that could be well trodden by European banks in the next two years, printing a holdco senior unsecured deal in the Tokyo Pro-Bond market as it looks to broaden its investor base for issuing loss absorbing debt.

Carlyle Group has sold its stake in RAC, the UK roadside recovery firm, to CVC Capital Partners in a deal that values the business at £2.2bn, including debt.

BPCE issued final guidance on Thursday for its latest multi-tranche Samurai sale, giving investors plenty of choice with two senior and three subordinated tranches.

The Australian dollar market, a popular funding pool for SSAs, will require a pragmatic approach in terms of price expectations next year, said senior SSA bankers.